ProPhase Labs (ProPhase Labs) Days Sales Outstanding : 1,027.76 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Days Sales Outstanding?

ProPhase Labs's average Accounts Receivable for the three months ended in Dec. 2023 was $39.41 Mil. ProPhase Labs's Revenue for the three months ended in Dec. 2023 was $3.50 Mil. Hence, ProPhase Labs's Days Sales Outstanding for the three months ended in Dec. 2023 was 1,027.76.

The historical rank and industry rank for ProPhase Labs's Days Sales Outstanding or its related term are showing as below:

PRPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.32 Med: 92.12 Max: 712.9
Current: 317.1

During the past 13 years, ProPhase Labs's highest Days Sales Outstanding was 712.90. The lowest was 47.32. And the median was 92.12.

PRPH's Days Sales Outstanding is ranked worse than
92% of 225 companies
in the Medical Diagnostics & Research industry
Industry Median: 69.24 vs PRPH: 317.10

ProPhase Labs's Days Sales Outstanding increased from Dec. 2022 (158.47) to Dec. 2023 (1,027.76).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

ProPhase Labs Days Sales Outstanding Historical Data

The historical data trend for ProPhase Labs's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Days Sales Outstanding Chart

ProPhase Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

91.99

50.11

47.32

83.46

319.68

ProPhase Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															158.47	178.23	263.76	421.15	1,027.76

Competitive Comparison of ProPhase Labs's Days Sales Outstanding

For the Diagnostics & Research subindustry, ProPhase Labs's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Days Sales Outstanding falls into.

ProPhase Labs Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

ProPhase Labs's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (37.568	+	40.177)	/	2 )	/	44.384	*	365
=	38.8725					/	44.384	*	365
=	319.68

ProPhase Labs's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (38.642	+	40.177)	/	2 )	/	3.499	*	365 / 4
=	39.4095					/	3.499	*	365 / 4
=	1,027.76

ProPhase Labs (NAS:PRPH) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

ProPhase Labs Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

ProPhase Labs (ProPhase Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530

Website

https://www.prophaselabs.com

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Executives

Morse Robert A. Jr.	officer: Controller	711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White	officer: Chief Financial Officer	191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr	director	902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel	10 percent owner	C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus	10 percent owner	188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch	director	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady	officer: Chief Accounting Officer	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr	officer: Chief Operating Officer	PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal	10 percent owner	THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank	director	104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin	director
Mark A. Burnett	10 percent owner	40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley	director, 10 percent owner, officer: Chairman, President, CEO	C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo	10 percent owner	17 WOLCOTT COURT, BOSTON MA 02136